Biotech blast

LOVE HIM or hate him, Paul Allen is still the man to see about Seattle’s new New Economy. Last week, Allen’s development company, Vulcan Inc., said it is committed to constructing a five-story biomedical building near South Lake Union. Analysts are predicting success, but the groundbreaking helps usher in a new era of real-estate speculation— a high-stakes gamble in which landlords essentially become venture capitalists for budding biotech firms.

Vulcan, one of the rare pioneering developers designing space specifically for biomedical companies, likely won’t have problems finding tenants. Estimates are that the demand for laboratory space in this city is as high as 5 million square feet. But drawing up the leases is a tricky business. Many newer biotech firms don’t have the capital to pay for the superexpensive structural accommodations they need, which can cost developers up to six times more than those for typical offices. And some start-ups may not live much longer than a microbe. So how do developers handle the risk?

Vulcan didn’t respond to Seattle Weekly by press time, but Ric Anderson of Lowe Enterprises Inc., who’s trying to lure biotech tenants to Lowe’s recently constructed building at 1616 Eastlake, says the leasing negotiations are taking his company into “uncharted water.” Lowe re-engineered its building with $1 million worth of last-minute design changes to accommodate biotech tenants. Now, Anderson says, Lowe has to decide whether to recover those costs up front or defer them.

Charlie Hampton, an associate broker with Cushman & Wakefield, says developers have reason to be nervous about biotech tenants. Recent headlines spell out the risk in black and white, such as when Wall Street darling ImClone Systems crashed after the Food and Drug Administration rejected its new drug Erbitux.

But Staubach Company president Bob Mooney, who represents biotech companies, says the realities of the biotech wave are going to require that developers invest more now and collect later, because a biotech company’s survival depends on investing in research and equipment, not rent. Mooney predicts that developers will easily recoup the cost of laboratory space over the long term.

If anyone can afford to wait, it’s Paul Allen.

Kevin Fullerton

kfullerton@seattleweekly.com


Talk to us

Please share your story tips by emailing editor@seattleweekly.com.

More in News & Comment

Screenshot from Amazon.com
Kent School Board votes to reject LGBTQ book ban decision

Multiple board members mentioned a need for policy changes in the book challenge process.

Photo of Auburn Police Officer Jeffrey Nelson after he shot and killed Jesse Sarey on May 31, 2019. Courtesy photo
Auburn police officer’s violent history could be used against him in court

Judge Nicole Gaines Phelps hasn’t yet decided whether it will be allowed in the trial.

File Photo
Data released on fireworks-related injuries in Washington

Last year fireworks caused $122,000 in damage.

File photo.
Mysterious in-home deaths of father, two daughters ruled as starvation

Written materials about fasting were found in the home; the father’s death called a suicide.

Dr. Faisal Khan. Courtesy of King County.
Dr. Faisal Khan appointed as next King County health director

Dennis Worsham will continue to serve as interim director until September 6.

Tsr
Renton spa employee accused of trying to coerce woman into prostitution, posing nude

Quyen T. Nguyen, 39, has been accused of attempted promotion of prostitution… Continue reading

Teaser
King County experts discuss extreme heat mitigation plan

The plan includes improving infrastructure and communications to prevent future disasters.

King County Prosecuting Attorney Dan Satterburg (File Photo)
King County Prosecuting Attorney vows to protect reproductive freedom

Dan Satterberg joins over 80 prosecutors from around the country in their pledge.

Most Read